28 February 2024 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
SCIENTIFIC RELEVANCE. Russia is pursuing a consistent government policy of import substitution and increasing the localisation of pharmaceutical manufacturing. The Strategy for the Development of the Pharmaceutical Industry until 2030 (Pharma-2030) includes the target share of medicinal products from the List of Strategic Medicines that should be fully localised. Since biotechnological medicinal products have high consumption growth rates and are listed as strategic medicines, it is a priority to study their production localisation process.AIM. This study aimed to analyse the degree of biopharmaceutical manufacturing localisation in Russia, considering the country of origin of active pharmaceutical ingredients (APIs).MATERIALS AND METHODS. The study used the State Register of Medicines and sales data of the DSM Group marketing agency. The authors used custom software for the Node.js® platform to determine the degree of production localisation.RESULTS. The analysis showed that the production process was fully localised for 25.6% (in packages) and 26.6% (in roubles) of all biotechnological medicinal products consumed in Russia in 2022. Imported medicinal products dominated the consumption structure, with a share of 33.9% in packages and 31.3% in roubles. Medicinal products with localised secondary packaging accounted for 5.8% in packages and 25.9% in roubles. Finished dosage forms produced using imported APIs had a significant share of 23.7% in packages and 6.2% in roubles. Russian APIs were used to produce 79% of the biotechnological medicinal products listed as strategic medicines, which corresponded to the full localisation of a share of the consumption structure of 10.8% in packages and 32.3% in roubles.CONCLUSIONS. The Russian biotechnological market remains heavily dependent on imported finished medicinal products and APIs. Although the Pharma-2030 target for the production of strategic biotechnological products has been achieved, the quantitative indicators show the necessity to increase output and localisation.
30 June 2022 in "Medical & Pharmaceutical Journal "Pulse"
The article presents the results of the analysis of the production and economic activities of Russian and foreign pharmaceutical companies in order to study modern approaches to risk management within the quality management system. Pharmaceutical enterprises are now actively implementing a quality management system, as this allows you to ensure and control quality at the required level throughout the entire life cycle of a medicinal product. Risk management in the pharmaceutical industry is an important component of the pharmaceutical quality system. Analysis of the position of risk management in the pharmaceutical industry in order to form the basis for the development of guidelines for effective risk management is an important area of research. The purpose of this article was to develop competent organizational solutions for the effective operation of a pharmaceutical enterprise related to the improvement of the quality management system through the implementation of effective risk management. The annual reports of pharmaceutical manufacturers of medicines for medical and veterinary use, pharmaceutical substances and substances used in pharmaceutical production were selected as research materials. The methods of information analysis, induction and synthesis were used as research methods. As a result of the work, a diverse approach of pharmaceutical enterprises to the categorization of risks, an uneven distribution of attention to different categories of risks, their underestimation and the need to develop a risk management manual were established, and measures were proposed to introduce this manual into the activities of pharmaceutical enterprises, including conferences and training courses to improve the competence of organizations in the processes of risk management and the involvement of government agencies in the implementation of risk management.
30 July 2022 in "Medical & Pharmaceutical Journal "Pulse"
The article presents the results of a price analysis of the Russian market of drugs used for the prevention of SARS and influenza. Due to the increase in demand for antiviral and immunomodulatory drugs caused by an increase in the incidence and the spread of a new coronavirus infection COVID-19, the population and various subjects of the Russian pharmaceutical market require objective information about price changes and the reasons why they occurred. The study was based on sales audit data for drugs used to prevent SARS and influenza, provided by the research company DSM Group. To analyze the price level, the arithmetic average weighted price per pack was determined, and to study the price dynamics, chain and basic price indices were calculated. The article presents information about prices for medicines used for the prevention of acute respiratory viral infections and influenza, and the dynamics of their changes in the Russian pharmaceutical market as a whole and in individual subjects of the Russian Federation, as well as in the context of their division into Russian and foreign medicines included in the List of vital essential and essential medicines and non-essential medicines, different price ranges. It has been established that in the past three years, against the backdrop of increased demand for antiviral and immunomodulatory drugs, their price growth rates have significantly exceeded the price growth rates in the entire Russian pharmaceutical market. The largest contribution to the increase in prices in the studied market segment is made by domestic drugs, the growth rates of which significantly exceed the growth rates of prices for imported products. Relatively high growth rates of prices for drugs included in the Vital and Essential Drugs List have been revealed, which over the past three years have significantly exceeded the growth rates for drugs that are not subject to price regulation. It is proposed to strengthen control over pricing and price dynamics in the segment of antiviral and immunomodulatory drugs in order to prevent high rates of price growth, which is especially relevant due to the continued high demand for them.
24 August 2025 in "Medical & Pharmaceutical Journal "Pulse"
The article presents the results of the analysis of the level and dynamics of prices for medicines in different subjects of the Russian Federation. This information is an important element that determines the accessibility of medical care for the population and the degree of their satisfaction with drug provision. The increase in the cost of medicines can have a significant impact on both the quality of life of an individual and the health care system as a whole. One of the specific factors influencing the pricing processes in the pharmaceutical market of the Russian Federation is territorial differences and socio-economic inequality between different entities, which affect the availability of medicines. To confirm the importance of the influence of this factor, a comparative analysis of price changes for pharmaceuticals was carried out, with regions with different socio-economic status, namely the federal cities of Moscow and St. Petersburg, as well as three Republics - Tatarstan, Dagestan and Yakutia - selected as individual subjects of the Russian Federation. An analysis of the level and dynamics of prices for medicines in the selected regions of Russia (the Republics of Tatarstan, Dagestan and Yakutia, and the federal cities of Moscow and St. Petersburg) showed significant regional differences related to socio-economic factors and market structure. As a result of the study, it was found that territorial differences and the socio-economic situation of the constituent entities of the Russian Federation is a specific factor affecting the dynamics of price changes for medicines. It was found that the highest price growth is characteristic of constituent entities of the Russian Federation with a low level of competition and a favorable economic situation of consumers.
9 October 2020 in Pharmacy Formulas
This article provides detailed results of an in-depth analysis of the price situation in the pharmaceutical market of Saint Petersburg, based on data from the audit of retail sales and hospital purchases, as well as the audit of preferential drug supply in 2012-2019, provided by the research company DSM Group. Using such statistical indicators as weighted average prices, weighted average prices index, Laspeyres price index and structural shifts index, the analysis of the level and dynamics of prices in the drug market of Saint Petersburg as a whole, as well as in its individual segments-retail, hospital and preferential drug provision segment. The results of a comparative analysis of price changes for medicines included in the List of essential and essential medicines and not included in it, for domestic and imported drugs, as well as for medicines belonging to different pharmacotherapeutic groups of Anatomic-therapeutic-chemical classification and located in different price ranges are presented.
30 July 2022 in "Medical & Pharmaceutical Journal "Pulse"
The article presents the results of the analysis of the level and dynamics of prices in the Russian market of gynecological preparations. Gynecological diseases are a serious obstacle in maintaining a high level of women's reproductive health. In accordance with official statistics, the number of gynecological patients is increasing every year in Russia, and there is also a “rejuvenation” of inflammatory and malignant diseases. In such conditions, the question of the quality and availability of drug provision for women with gynecological preparations arises, which, in turn, depends on the level and dynamics of prices in the corresponding market segment. An analysis of the dynamics of price changes in the Russian market of gynecological preparations was carried out using the index method of analysis, based on the construction and calculation of price indices and allowing to identify factors that affect price growth. It has been established that prices on the Russian market of gynecological drugs have been growing for a long period of time at a rate comparable to the growth rates of prices on the entire Russian pharmaceutical market, however, in certain time periods, the discrepancies can be significant and exceed 5% per year. As a result of the study, groups of gynecological drugs with the highest price growth rates were identified, among which drugs not included in the Vital and Essential Drugs List, domestic and generic drugs can be distinguished. Among the subgroups of the ATC classification, both in terms of price growth rates and in terms of the level of the weighted average price per pack, the G03 subgroup “Sex hormones and modulators of the reproductive system” is in the lead. In order to prevent higher rates of price growth in the studied market segment and ensure the availability of drug supply, it is proposed to conduct regular monitoring of price changes and, if an unfavorable development of the price situation is detected, make operational management decisions.